Abstract
CAR-T is a genetically engineered autologous T cell as a "live drug" targeting CD19. As a new tumor treatment method in recent years, CAR-T has been quite effective in DLBCL treatment. In the process of tumor treatment, the tumor appeared immune escape, so modern scientists modified T cells into CART through experiments. The common targets of CAR-T are CD19, BCMA, etc., and the appearance of targets has been reduced to a certain extent The emergence of immune escape, and the application of dual-target CAR-T further mitigated this problem. However, when CAR-T therapy is implemented in vivo, it is affected by the tumor micro environment, which inhibits its treatment effect. This article discusses the role and positive influence of multi-target cart in the treatment of NHL discuss and explore the negative influence of its efficacy in the micro environment.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
